Panson announced the signing of a privatization agreement and the transaction is expected to be completed in the first quarter of next year
楚一帆
发表于 2023-10-12 14:15:17
242
0
0
Under the agreement, Panson will merge with the parent company (New Genetron Holding Limited), and Panson will continue as a surviving entity and become a wholly-owned subsidiary of the parent company. The buyer group participating in the transaction includes CICC Concord Medical Fund, Wealth Strategy Holding Limited, Wuxi Guolian Group, CCB (Beijing) Investment Fund Management Co., LTD., Wuxi Huihong Yingkang Investment Partnership (Limited Partnership), etc.
According to the agreement, the purchase price per ordinary share is $0.272 and the purchase price per American Depositary Share (" ADS ", where each ADS represents five ordinary shares) is $1.36. According to the signed agreement, the transaction price represents a premium of approximately 15% to the last trading day before Panson announced that it had received the privatization offer; The offer represents a 21 per cent premium to the average closing price in the 30 trading days prior to the announcement of the take-private offer. As of October 11, 2023, the last trading day before the announcement, the premium is 42%.
The privatization transaction is expected to be completed in the first quarter of 2024, the announcement said.
Public information shows that Panson is a global cutting-edge precision cancer medicine company, providing early cancer screening, diagnosis and monitoring, drug research and development services covering the full cycle of cancer products and services, comprehensive coverage of China's top ten cancer types, and has "one step method", Mutation Capsule and other original research patented technology. In addition, Panson is the only precision medical enterprise that has entered the national major project of early screening of liver cancer, lung cancer, digestive tract cancer and other cancers of the Ministry of Science and Technology, and its lung cancer precision diagnosis and treatment project won the second prize of National Science and Technology Progress.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Boeing reaches agreement with largest union to avoid strike
- The iPhone 16 will ignite a wave of phone swapping! Wedbush: Apple's market value is expected to reach $4 trillion next year
- Guoyin Jinzhu: Signed an aircraft purchase agreement with Boeing to purchase 50 737-8 aircraft
- Apple is also developing a new foldable iPhone with a foldable screen, which may be unveiled as early as next year
- Will there be an oversupply of HBM next year? Institutional warning: Half of the production capacity cannot be sold
- Tianjing Biotechnology and Sanofi have reached an authorization agreement with a potential total price of up to 200 million euros
- Major changes! NVIDIA AI servers are expected to adopt slot design for the first time next year
- OPEC+reportedly strengthens supervision and vows to reshape the authority of the production reduction agreement
- Apple Vision Pro 2 is expected to be mass-produced next year, with "AI+spatial computing" becoming the biggest selling point?
- Will Apple launch a 3000 yuan smartphone next year? There are two major changes
-
AIエクスプレスによると、10月3日、米株の人気の中概株盤の前が低くなり、ピッピッピッと5%近く下落し、相多、名創優品、小鵬自動車は3%超下落し、百度、蔚来自動車、京東は2%超下落した。 ...
- SOGO
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏
-
ナスダック中国の金龍指数は5%超上昇し、楽しい自動車は120%超上昇し、金山雲は18%超上昇し、ピシャリと12%超上昇し、子牛の電動、怪獣の充電は10%超上昇し、愛奇芸は8%超上昇し、テンセント音楽、新東方は7%超上昇 ...
- hecgdge4
- 前天 10:28
- 支持
- 反对
- 回复
- 收藏
-
米非農業雇用データが発表され、FRBの利下げペースは鈍化したか。 現地時間10月4日、米国の最新の非農業雇用データは予想をはるかに上回った。市場はFRBの利下げペースが鈍化すると予想している。このデータが発表 ...
- 内托体头
- 10 小时前
- 支持
- 反对
- 回复
- 收藏
-
EUが中国の電気自動車に関税を課す方針、独首相と財務相が反発 ドイツ連邦のショルツ首相は現地時間の10月2日、EUが中国の電気自動車に一時的な補助金税を課す紛争を解決するために中国と交渉することを表明した。 ...
- 寒郁轩良
- 昨天 10:13
- 支持
- 反对
- 回复
- 收藏